Get the Stockscreener App
8.11
0.75%
0.06
Pre-market:
8.07
-0.04
-0.49%
Adicet Bio Inc stock is traded at $8.11, with a volume of 32,008.
It is up +0.75% in the last 24 hours and up +5.60% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
See More
Previous Close:
$8.05
Open:
$8.12
24h Volume:
32,008
Relative Volume:
0.28
Market Cap:
$75.81M
Revenue:
$24.99M
Net Income/Loss:
$-108.83M
P/E Ratio:
-0.5396
EPS:
-15.0286
Net Cash Flow:
$-91.62M
1W Performance:
+12.33%
1M Performance:
+5.60%
6M Performance:
+2.40%
1Y Performance:
-32.44%
1-Day Range:
$8.11
$8.3694
1-Week Range:
$7.02
$8.3694
52-Week Range:
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
8.11 | 75.81M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Adicet Bio Inc. (ACET) Q1 2026 Earnings: Narrowed Loss Beats Street on Cost Discipline, Pipeline ProgressEBITDA Estimate Trend - newsline.com
Adicet Bio teases autoimmune data catalysts, PSMA plans at Jefferies conference - MSN
ACET Q1 2026 Earnings: Better-than-Expected Losses Lift SharesAdjusted Earnings Analysis - newsline.com
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
BPAS - FinancialContent
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference - sharewise.com
Adicet Bio (ACET) Slips Nearly 6% as Shares Test Key Support LevelsLong Short Pair - newsline.com
Adicet Bio Inc. (ACET) Surges 7.75% as Bullish Momentum BuildsDividend Arbitrage - The Legal Advocate
Are medical stocks lagging Adicet Bio (ACET) this year? - MSN
ACET Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 7.75% Share LiftProfit Inflection Point - newsline.com
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
Adicet Bio Inc. (ACET) Rises 1.65% as Biotech Sector Shows Mixed SignalsVolume Breakout Ideas - newsline.com
Adicet Bio (ACET) Edges Higher: Modest Gain Amid Key Support and Resistance LevelsBollinger Band - The Legal Advocate
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade - Yahoo Finance
Adicet Bio Shares Halted Ahead of Data Readout That May Steer ACET - Bez Kabli
Adicet Bio (ACET) Shows Resilient Move, Testing Key Resistance After 3.4% GainVerified Analyst Reports - Newser
ACET Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponsePreliminary Results - newsline.com
Adicet Bio (ACET) Q1 2026 Earnings: EPS $-1.88 Beats EstimatesRevenue Beat Analysis - Newser
Adicet Bio, Inc. 2025 10-K/A Annual Report: Controls, Procedures & Internal Control Certifications - Minichart
Adicet Bio (ACET) updates 10-K to confirm effective 2025 controls - Stock Titan
ACET Stock Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Adicet Bio (ACET) Falls -2.34% — Watching $7.12 Support 2026-05-18Total Put Call - newsline.com
Adicet Bio (ACET) price target decreased by 34.28% to 35.53 - MSN
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
TradingKey - TradingKey
Adicet Bio CEO to discuss cell therapies at Jefferies health conference - Stock Titan
JonesTrading Initiates Adicet Bio(ACET.US) With Buy Rating, Announces Target Price $20 - Moomoo
Press Release Service: Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adicet Bio (NASDAQ: ACET) cuts Q1 2026 loss while advancing prula-cel and ADI-212 pipeline - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - New Castle News
Lupus, arthritis and prostate cancer: new cell trials planned by Adicet Bio - Stock Titan
ACET Stock Price, Quote & Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
Jefferies Initiates Adicet Bio(ACET.US) With Buy Rating, Announces Target Price $19 - Moomoo
Jefferies initiates Adicet Bio stock with buy rating, $19 target By Investing.com - Investing.com Australia
Jefferies initiates Adicet Bio stock with buy rating, $19 target - Investing.com India
Johnson & Johnson Sells 341,693 Shares of Adicet Bio, Inc. $ACET - MarketBeat
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Adicet Bio (NASDAQ:ACET) Rating Increased to Sell at Wall Street Zen - MarketBeat
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):